|
18/09/2024
|
07:00
|
Fasenra EGPA US FDA approval
|
RNS
|
|
13/09/2024
|
15:15
|
Director/PDMR Shareholding
|
RNS
|
|
02/09/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
16/08/2024
|
07:00
|
Imfinzi approved in US for resectable lung cancer
|
RNS
|
|
01/08/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
30/07/2024
|
07:00
|
AstraZeneca prices a €1.4bn bond offering
|
RNS
|
|
29/07/2024
|
08:41
|
Stabilisation Notice - ASTRAZENECA
|
RNS
|
|
29/07/2024
|
07:00
|
Calquence fixed-duration combo improved 1L CLL PFS
|
RNS
|
|
26/07/2024
|
07:00
|
ODAC reviewed Imfinzi in resectable lung cancer
|
RNS
|
|
25/07/2024
|
07:00
|
Half-year Report
|
RNS
|
|
15/07/2024
|
07:00
|
Acquisition of Amolyt Pharma completed
|
RNS
|
|
01/07/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
01/07/2024
|
07:00
|
Lynparza & Imfinzi positive CHMP in endometrial
|
RNS
|
|
25/06/2024
|
07:05
|
Update on Imfinzi ADJUVANT BR.31 trial
|
RNS
|
|
25/06/2024
|
07:00
|
Imfinzi improved EFS and OS in bladder cancer
|
RNS
|
|
18/06/2024
|
07:00
|
Update on CAPItello-290 Phase III trial
|
RNS
|
|
17/06/2024
|
07:00
|
Imfinzi approved in the US for endometrial cancer
|
RNS
|
|
12/06/2024
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
05/06/2024
|
07:00
|
Acquisition of Fusion completed
|
RNS
|
|
03/06/2024
|
15:05
|
Block listing Interim Review
|
RNS
|
|
03/06/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
03/06/2024
|
07:00
|
Tagrisso plus chemo recommended for approval in EU
|
RNS
|
|
28/05/2024
|
07:00
|
Dato-DXd improved OS in nonsquamous lung cancer
|
RNS
|
|
21/05/2024
|
07:00
|
AstraZeneca to deliver $80bn revenue by 2030
|
RNS
|
|
20/05/2024
|
07:00
|
AstraZeneca to manufacture ADCs in Singapore
|
RNS
|
|
16/05/2024
|
07:00
|
SUPERNOVA Trial Met COVID-19 prevention endpoint
|
RNS
|
|
15/05/2024
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
07/05/2024
|
07:00
|
AstraZeneca completes Cellectis equity investment
|
RNS
|
|
02/05/2024
|
07:00
|
Calquence combination improved PFS in 1L MCL
|
RNS
|
|
01/05/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
29/04/2024
|
07:05
|
Truqap recommended for EU breast cancer approval
|
RNS
|
|
29/04/2024
|
07:00
|
Enhertu improved PFS in HER2-low and ultralow
|
RNS
|
|
25/04/2024
|
07:00
|
1st Quarter Results
|
RNS
|
|
11/04/2024
|
17:30
|
Result of AGM
|
RNS
|
|
11/04/2024
|
07:00
|
AstraZeneca increases 2024 dividend by 7%
|
RNS
|
|
08/04/2024
|
07:00
|
Enhertu approved in US for HER2+ solid tumours
|
RNS
|
|
05/04/2024
|
07:00
|
Imfinzi improved OS & PFS in limited-stage SCLC
|
RNS
|
|
02/04/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
02/04/2024
|
07:05
|
Voydeya approved in US
|
RNS
|
|
02/04/2024
|
07:00
|
FDA accepts Dato-DXd BLA for breast cancer
|
RNS
|
|
25/03/2024
|
07:00
|
Ultomiris approved in the US for NMOSD
|
RNS
|
|
19/03/2024
|
07:00
|
AstraZeneca to acquire Fusion
|
RNS
|
|
14/03/2024
|
07:00
|
AstraZeneca to acquire Amolyt
|
RNS
|
|
12/03/2024
|
11:00
|
Director/PDMR Shareholding
|
RNS
|
|
07/03/2024
|
11:00
|
Notice of AGM
|
RNS
|
|
06/03/2024
|
15:05
|
Director/PDMR Shareholding
|
RNS
|
|
06/03/2024
|
15:00
|
Director/PDMR Shareholding
|
RNS
|
|
04/03/2024
|
07:00
|
EMA validates Dato-DXd MAAs for NSQ NSCLC and BC
|
RNS
|
|
01/03/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
26/02/2024
|
07:00
|
Voydeya recommended for EU approval
|
RNS
|